Evaluation of Apelin-13 and Apelin-36 in Women With Recurrent Pregnancy Loss

Evaluation of Apelin-13 and Apelin-36 Concentrations in Women With Primary Unexplained Recurrent Pregnancy Loss

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05205044

Enrollment

Registered

2022-01-24

Start date

2022-01-23

Completion date

2023-01-30

Last updated

2023-02-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent Pregnancy Loss

Brief summary

Lower Apelin levels are associated with hypertensive disorders with pregnancy, yet no studies investigated its levels in recurrent pregnancy loss

Interventions

DIAGNOSTIC_TESTApelin-13, Apelin-36

Serum levels of Apelin-13 and Apelin-36

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 40 Years

Inclusion criteria

* pregnant women in first trimester * negative antiphospholipid markers * normal karyotype

Exclusion criteria

* multiple pregnancy * fetal malformations * maternal diseases * smoking or alcohol use * history of or risk factors for preterm labor

Design outcomes

Primary

Measure	Time frame	Description
Apelin-13 and Apelin-36	1 year	Serum levels of Apelin-13 and Apelin-36

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026